7TM Pharma enters agreement with Johnson & Johnson company  

2005.06.10
Denmark's 7TM Pharma has entered an important contract with Ortho-McNeil Pharmaceutical, a Johnson & Johnson company, to develop compounds for the treatment of asthma and allergic diseases

7TM Pharma, a Danish biotech company based north of Copenhagen, has entered an exclusive worldwide licence agreement and research collaboration with Ortho-McNeil Pharmaceutical, a Johnson & Johnson company, to further develop 7TM Pharma's programme on novel oral compounds for the treatment of asthma and allergic diseases. The Danish biotech firm will receive an upfront fee, research funding and milestone payments, as well as royalties on sales for each compound developed under the collaboration.

The agreement is 7TM Pharma's second major collaboration announced in 2005. In April, the company entered an agreement with Procter & Gamble Pharmaceuticals to undertake a joint research programme in therapeutic angiogenesis, with the aim of identifying drug candidates for the treatment of cardiovascular diseases related to arteriosclerosis. The news is reported by national daily newspaper Berlingske Tidende and on 7TM Pharma's website.

7TM Pharma is a drug discovery and development company which has a pipeline of advanced programmes in its main therapeutic focus area, obesity. The biotech company's pipeline also include programmes on well validated targets in allergy/inflammation, therapeutic angiogenesis and cardiovascular diseases. Investors in 7TM Pharma include Novo, Dansk Innovationsinvestering, Alta Partners, Index Ventures and Baker-Tisch Investments.

Link > 7TM Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×